AstraZeneca halts mid-stage trial of asthma candidate AZD9412

13 October 2016

Respiratory drug discovery company Synairgen (LSE: SNG) says it has been advised by its development partner AstraZeneca (LSE: AZN) that it has “decided to stop the Phase IIa trial of AZD9412 based on an interim analysis, where an overall very low number of reported severe exacerbations could make primary endpoint conclusions difficult.”

AstraZeneca said it will now review the data and study design “before deciding on the best way forward for the program.” The full results will be available in the first quarter of next year. It added: "The interim analysis confirmed the positive safety and tolerability profile seen in previous trials, and inhaled IFN-b [interferon beta] remains an interesting treatment opportunity for patients with respiratory disease.”

The news on Wednesday sent the share shares of Synairgen – which licensed the inhaled interferon beta program to AstraZeneca in 2014 under at $232 million deal – plunging as much as 34%, while AstraZeneca fell 1.8% to £49.58.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK